Defining milestones for the study of remyelination using the cuprizone mouse model: How early is early?

Filipe Palavra,Sofia D. Viana,Sara Henriques,João Dinis,João Martins,Maria H. Madeira,Raquel Santiago,Lorena Petrella,José Sereno,Miguel Castelo-Branco,Frederico C. Pereira,Luís Almeida,António F. Ambrósio,Flávio Reis
DOI: https://doi.org/10.1016/j.msard.2022.103886
IF: 4.808
2022-07-01
Multiple Sclerosis and Related Disorders
Abstract:BackgroundCuprizone (CPZ) is a copper chelator used to produce a reversible oligodendrocytopathy in animals, which has some similarities to the pathology found in human multiple sclerosis (MS). This model is attractive to study remyelination.AimsTo demonstrate that a two-week period after cessation of CPZ exposure is sufficient to establish changes compatible with remyelination, without accompanying behavior or brain magnetic resonance imaging (MRI) disturbances.MethodsTwo groups of male C57BL/6 mice were fed an oral solution of CPZ (0.2%) for 5 weeks (W5); half of the animals were kept under the vehicle for another 2 weeks (W7). After 5 and 7 weeks, animals were subjected to a battery of behavioural tests and 18 animals to brain MRI. Animals’ cerebellar samples were studied for gene expression and/or protein levels of GFAP, myelin proteolipid protein (PLP), TNF-α and IL-1β.ResultsNo differences were observed between CPZ-exposed and control animals, regarding behavior and MRI, both at W5 and W7. However, myelin PLP levels decreased in CPZ (W5) treated animals, and these changes reverted at W7. GFAP levels varied in the opposite direction.ConclusionsObserved changes validate the use of W5 and W7 temporal moments for the study of demyelination and early remyelination in this model.
clinical neurology
What problem does this paper attempt to address?